PEN Stock Summary and Trading Ideas (Penumbra | NYSE:PEN)

Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.

Penumbra trades on the NYSE stock market under the symbol PEN.

As of July 14, 2026, PEN stock price declined to $316.26 with 646,446 million shares trading.

PEN has a beta of -0.46, meaning it tends to be less sensitive to market movements. PEN has a correlation of 0.04 to the broad based SPY ETF.

PEN has a market cap of $12.44 billion. This is considered a Large Cap stock.

Last quarter Penumbra reported $375 million in Revenue and $1.01 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.07.

In the last 3 years, PEN traded as high as $362.41 and as low as $148.00.

The top ETF exchange traded funds that PEN belongs to (by Net Assets): IJH, VTI, VB, VBK, VXF.

PEN has outperformed the market in the last year with a return of +32.9%, while the SPY ETF gained +21.8%. However, in the most recent history, PEN shares have underperformed the stock market with its stock returning -4.6% in the last 3 month period and +0.3% for the last 2 week period, while SPY has returned +9.9% and +1.5%, respectively.

PEN support price is $317.40 and resistance is $320.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PEN shares will trade within this expected range on the day.